Merck Suspends Gardasil Shipments to China, Lowers 2025 Revenue Forecast

Merck has temporarily halted shipments of its cancer vaccine Gardasil to China, lasting at least through mid-202512.

The company lowered its 2025 revenue guidance to between $64.1 billion and $65.6 billion, falling short of analysts' expectations of $67.31 billion12.

Gardasil is a vaccine that prevents certain types of cancer caused by human papillomavirus (HPV)2.

The suspension of shipments to China has led Merck to withdraw its previous $11 billion sales target for Gardasil1.

This decision comes as demand for the vaccine in China has significantly decreased1.

The suspension and lowered revenue forecast have impacted Merck's financial outlook for 2025, causing concern among investors and analysts12.

Sources:

1. https://vistapglobal.com/category/topics/

2. https://www.beckershospitalreview.com/pharmacy/mercks-2025-outlook-falls-on-cancer-vaccine-china-shipment-pause.html